XML 21 R4.htm IDEA: XBRL DOCUMENT v3.23.2
Condensed Consolidated Statements of Operations (Unaudited) - USD ($)
shares in Thousands, $ in Thousands
 3 Months Ended 6 Months Ended
Jun. 30, 2023
Jun. 30, 2022
Jun. 30, 2023
Jun. 30, 2022
Revenue:        
Total revenue $ 44,319 $ 29,806 $ 80,480 $ 90,633
Operating costs and expenses:        
Cost of goods sold $ 5,708 $ 6,809 $ 9,199 $ 11,048
Cost, Product and Service [Extensible List] Product Revenue, Net [Member] Product Revenue, Net [Member] Product Revenue, Net [Member] Product Revenue, Net [Member]
Research and development $ 95,478 $ 70,963 $ 169,964 $ 159,981
Selling, general and administrative 31,181 30,258 65,455 60,820
Total operating costs and expenses 132,367 108,030 244,618 231,849
Loss from operations (88,048) (78,224) (164,138) (141,216)
Interest and other, net        
Interest expense (3,069) (141) (5,441) (238)
Interest income and other income (expenses), net 2,652 5,199 3,687 4,876
Total interest and other, net (417) 5,058 (1,754) 4,638
Loss before income taxes (88,465) (73,166) (165,892) (136,578)
Provision for (benefit from) income taxes (235) 23 (161) 136
Investment income in unconsolidated variable interest entity 550 565 1,346 885
Net loss $ (87,680) $ (72,624) $ (164,385) $ (135,829)
Net loss per share - basic $ (0.90) $ (0.78) $ (1.71) $ (1.46)
Net loss per share - diluted $ (0.90) $ (0.78) $ (1.71) $ (1.46)
Weighted average number of common shares used to calculate net loss per share:        
Basic 97,729 93,475 96,218 93,260
Diluted 97,729 93,475 96,218 93,260
License Revenue [Member]        
Revenue:        
Total revenue $ 1,000 $ 0 $ 7,000 $ 22,590
Development and Other Revenue [Member]        
Revenue:        
Total revenue 5,158 5,457 9,050 17,219
Product Revenue, Net [Member]        
Revenue:        
Total revenue 23,889 23,256 48,049 42,137
Drug Product Revenue, Net [Member]        
Revenue:        
Total revenue $ 14,272 $ 1,093 $ 16,381 $ 8,687